Cost-effectiveness analysis of pegylated-liposomal doxorubicin and liposomal daunorubicin treatments in patients with Kaposi's sarcoma

Acta Oncologica

Volumn 38, Issue 8, 1999, Pages 1063-1067

  Hjortsberg, Catharina ^a   Persson, Ulf ^a   Lidbrink, Elisabet ^c   Bennett, Charles ^b  

^a SWEDISH INSTITUTE FOR HEALTH ECONOMICS   (Sweden)

^b NW Univ Feinberg School of Medicine   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; DAUNORUBICIN; DOXORUBICIN; VINCRISTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG SENSITIVITY; HOMOSEXUALITY; HUMAN; HUMAN CELL; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT PLANNING;

EID: 0033427746     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418699432374     Document Type: Article

References (20)

1. Centers for disease control and prevention. HIV AIDS surveillance report, Atlanta, GA: Centers for Disease Control, February 1993: 1-23.
2. Hermans P, Lundgren JD, Sommereijns B, et al. Epidemiology of AIDS-related Kaposi's sarcoma in Europe over 10 years. AIDS 1996; 10: 911-7.
3. Lundgren JD, Melbye M, Pedersen C, Rosenberg PS, Gerstoft J. Changing patterns of Kaposi's sarcoma in Danish AIDS patients with complete follow-up. Am J Epidemiol 1995; 141: 652.
4. Lifson AR, Darrow WW, Hessol NA, et al. Kaposi's sarcoma in a cohort of homosexual and bisexual men. Am J Epidemiol 1990; 131: 221-31.
5. Rutherford GW, Payne SF, Lemp GF. The epidemiology of AIDS-related Kaposi's sarcoma in San Fransisco. J AIDS 1990; 3 (Suppl 1): 4-7.
6. Schechter MT, Marion SA, Elmslie KD, Ricketts MN, Nault P, Archibald CP. Geographic and birth cohort associations of Kaposi's sarcoma among homosexual men in Canada. Am J Epidemiol 1991; 134: 485-8.
7. Lundgren JD. Kaposi's sarcoma and its management in AIDS patients - recommendations from a Scandinavian study group. Scand J Infect Dis 1997; 29: 3-12.
8. Brenner AJ, Spencer CM. Liposomal encapsulation: making old and new drugs do new tricks. J Natl Cancer Inst 1989; 81: 13-5.
9. Coukell AJ, Spencer CM. Polyethylene glycol-liposomal doxorubicin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma. Drugs 1997; 53: 520-38
10. Stewart JSW, Jablonski H, Goebel FD, et al. A randomized comparative trial of liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. Proc Am Soc Clin Oncol 1997; 190A.
11. Gill PS, Wernz J, Scadden DT, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 1996; 14: 2353-64.
12. Northfelt DW, Dezuble BJ, Thommes JA, et al. Pegylated-liposomal doxorubin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 1998; 16: 2445-51.
13. Gill PS, Wernz J, Myers A, et al. Liposomal encapsulated daunorubicin in AIDS-related pulmonary Kaposi's sarcoma. Proc Am Soc Clin Oncol 1997; 16: 55A.
14. Krown SE, Metroka C, Wernz J. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluating, response, and staging. J Clin Oncol 1989; 7: 1201-7.
15. FASS. Farmaceutiska specialiteter i Sverige (Pharmaceutical Specialities in Sweden). Stockholm: Lakemedelsinformation AB, 1998.
16. Swedish corporation of county councils. Kostnader per intagen patient 1993 (Costs per admitted patient 1993). Stockholm, 1993.
17. Northfelt DW. AIDS-related Kaposi's sarcoma: still a problem, still an opportunity. J Clin Oncol 1994; 12: 1109-10.
18. Northfelt DW, Dezuble BJ, Thommes JA, et al. Doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J Clin Oncol 1997; 15: 653-9.
19. Savage GE, Gable C, Motte K, Dixon C, Becker R. A pharmacokinetic analysis of Kaposi's sarcoma patients based on a clinical trail of ABV versus liposomal daunorubicin. Proc XIth Interntl Conf on AIDS, Canada, 1996.
20. Bennett LC, Golub RM, Stinson TS, et al. A cost-effectiveness analysis comparing liposomal anthracyclines in the treatment of AIDS-related Kaposi's sarcoma. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18: 460-5.